All Stories

Trump crosses party lines to back Medicare drug-price negotiation

Alok Saboo Democratic presidential candidates Hillary Clinton and Bernie Sanders have already taken aim at pharma, talking up plans to give Medicare power to negotiate drug prices. ...

Kochenderfer: ‘I think the main focus of the CAR field will be autologous cells…’

John Carroll Yesterday there was a brief, digital dust-up on Twitter over an abstract circulating online on a CAR-T study undertaken from the NCI's James Kochenderfer, one of the ...

Revved-up Tecfidera sales power Biogen in Q4

Eric Palmer Biogen CEO George Scangos and his team tamped down investor expectations earlier this month at the J.P. Morgan Healthcare Conference, saying that the company faced headwinds. ...

Merck lines up for a quick approval with its C. diff therapy

Damian Garde Merck is nearing FDA approval for its Clostridium difficile-fighting antibody, picking up the agency's priority review designation with the promise of a shortened vetting ...

Novartis CEO Jimenez sees U.S. pricing power draining away

Carly Helfand Remember the days when drugmakers could raise prices without sparking political pushback? Novartis CEO Joe Jimenez does–and he says they're not coming back. FiercePharma ...

A look at pharma’s many TV spokes-creatures

Damian Garde Over the past decade, pharma companies have increasingly relied on animated characters to advertise their products, using cute, quaint or questionable creatures to illustrate ...

Lilly, BI approach CV-benefit label change for SGLT2 med Jardiance

Carly Helfand Eli Lilly and Boehringer Ingelheim are one step closer to an important label change for SGLT2 contender Jardiance. FiercePharma News

Backed by Novartis and Orbimed, Adicet joins immunotherapy crowd with $51M round

John Carroll Adicet Bio has jumped out of stealth mode–more or less–with a $ 51 million A round and plans to combine two platform technologies into a next-gen approach ...

Langer-backed biotech reboots with $38M, new name and new cancer drug tech

John Carroll Four-year-old biotech Blend Therapeutics, launched with the scientific backing of MIT's Robert Langer and colleagues, is jettisoning its one-time lead drug program ...

Facing extinction, MannKind is reportedly looking to sell itself

Damian Garde Struggling drugmaker MannKind is looking for a way out of its perilous financial situation, according to Reuters, scouting for a buyer in the wake of ex-partner Sanofi's ...

Novartis divvies up troubled Alcon; targets $1B in cuts in R&D and manufacturing rejig

Tracy Staton Novartis has a problem with its eye-care unit Alcon: It's not performing. As expected, the division dragged down the Swiss drugmaker's fourth-quarter and full-year ...

Novartis reshuffles its $9B R&D operation to save $1B a year

Damian Garde Swiss pharma giant Novartis is changing up its massive R&D organization in hopes of squeezing out some savings while betting big on new medicines. FierceBiotech News
Page 4 of 839« First...23456...102030...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS